Your browser doesn't support javascript.
loading
Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies.
Raina, Kanak; Forbes, Chris D; Stronk, Rebecca; Rappi, Jonathan P; Eastman, Kyle J; Zaware, Nilesh; Yu, Xinheng; Li, Hao; Bhardwaj, Amit; Gerritz, Samuel W; Forgione, Mia; Hundt, Abigail; King, Madeline P; Posner, Zoe M; Correia, Allison D; McGovern, Andrew; Puleo, David E; Chenard, Rebekka; Mousseau, James J; Vergara, J Ignacio; Garvin, Ethan; Macaluso, Jennifer; Martin, Michael; Bassoli, Kyle; Jones, Kelli; Garcia, Marco; Howard, Katia; Yaggi, Madeleine; Smith, Levi M; Chen, Jinshan M; Mayfield, Andrew B; De Leon, Cesar A; Hines, John; Kayser-Bricker, Katherine J; Crews, Craig M.
Afiliación
  • Raina K; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Forbes CD; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Stronk R; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Rappi JP; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Eastman KJ; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Zaware N; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Yu X; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Li H; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Bhardwaj A; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Gerritz SW; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Forgione M; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Hundt A; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • King MP; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Posner ZM; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Correia AD; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • McGovern A; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Puleo DE; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Chenard R; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Mousseau JJ; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Vergara JI; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA.
  • Garvin E; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Macaluso J; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Martin M; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Bassoli K; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Jones K; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Garcia M; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Howard K; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Yaggi M; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Smith LM; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Chen JM; Halda Therapeutics OpCo Inc, New Haven, CT, USA.
  • Mayfield AB; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA.
  • De Leon CA; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA.
  • Hines J; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA.
  • Kayser-Bricker KJ; Halda Therapeutics OpCo Inc, New Haven, CT, USA. Electronic address: kat.kayser-bricker@haldathera.com.
  • Crews CM; Department of Molecular, Cellular, & Developmental Biology, Yale University, New Haven, CT, USA; Department of Pharmacology, Yale University, New Haven, CT, USA; Department of Chemistry, Yale University, New Haven, CT, USA. Electronic address: craig.crews@yale.edu.
Cell Chem Biol ; 31(8): 1490-1502.e42, 2024 Aug 15.
Article en En | MEDLINE | ID: mdl-39116881
ABSTRACT
We describe a protein proximity inducing therapeutic modality called Regulated Induced Proximity Targeting Chimeras or RIPTACs heterobifunctional small molecules that elicit a stable ternary complex between a target protein (TP) selectively expressed in tumor cells and a pan-expressed protein essential for cell survival. The resulting co-operative protein-protein interaction (PPI) abrogates the function of the essential protein, thus leading to death selectively in cells expressing the TP. This approach leverages differentially expressed intracellular proteins as novel cancer targets, with the advantage of not requiring the target to be a disease driver. In this chemical biology study, we design RIPTACs that incorporate a ligand against a model TP connected via a linker to effector ligands such as JQ1 (BRD4) or BI2536 (PLK1) or CDK inhibitors such as TMX3013 or dinaciclib. RIPTACs accumulate selectively in cells expressing the HaloTag-FKBP target, form co-operative intracellular ternary complexes, and induce an anti-proliferative response in target-expressing cells.
Asunto(s)
Antineoplásicos; Proteínas de Ciclo Celular; Bibliotecas de Moléculas Pequeñas; Humanos; Proteínas de Ciclo Celular/metabolismo; Proteínas de Ciclo Celular/antagonistas & inhibidores; Bibliotecas de Moléculas Pequeñas/química; Bibliotecas de Moléculas Pequeñas/farmacología; Bibliotecas de Moléculas Pequeñas/síntesis química; Antineoplásicos/farmacología; Antineoplásicos/química; Antineoplásicos/síntesis química; Neoplasias/tratamiento farmacológico; Neoplasias/metabolismo; Neoplasias/patología; Proliferación Celular/efectos de los fármacos; Triazoles/química; Triazoles/farmacología; Quinasa Tipo Polo 1; Proteínas Serina-Treonina Quinasas/metabolismo; Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores; Azepinas/farmacología; Azepinas/química; Proteínas Proto-Oncogénicas/metabolismo; Proteínas Proto-Oncogénicas/antagonistas & inhibidores; Factores de Transcripción/metabolismo; Factores de Transcripción/antagonistas & inhibidores; Indolizinas/química; Indolizinas/farmacología; Línea Celular Tumoral; Compuestos Bicíclicos Heterocíclicos con Puentes/química; Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología; Ligandos; Inhibidores de Proteínas Quinasas/farmacología; Inhibidores de Proteínas Quinasas/química; Inhibidores de Proteínas Quinasas/síntesis química; Compuestos Heterocíclicos con 2 Anillos/farmacología; Compuestos Heterocíclicos con 2 Anillos/química; Compuestos Heterocíclicos con 2 Anillos/síntesis química; Proteínas Nucleares/metabolismo; Proteínas Nucleares/antagonistas & inhibidores; Proteínas que Contienen Bromodominio; Óxidos N-Cíclicos; Compuestos de Piridinio
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas de Ciclo Celular / Bibliotecas de Moléculas Pequeñas / Antineoplásicos Idioma: En Revista: Cell Chem Biol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas de Ciclo Celular / Bibliotecas de Moléculas Pequeñas / Antineoplásicos Idioma: En Revista: Cell Chem Biol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos